Decreased Striatal Vesicular Monoamine Transporter Type 2 Correlates With the Nonmotor Symptoms in Parkinson Disease.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Nonmotor symptoms (NMS) are critical players in the patients' quality of life in Parkinson disease (PD). Vesicular monoamine transporter type 2 (VMAT2) has been reported owing to a role in affecting dopamine neurons in the striatum. Therefore, this study set out to characterize the relationship between VMAT2 distribution in the striatum in relation to the NMS in PD.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Clin Nucl Med

Title: Clinical nuclear medicine

Publisher: Ovid Technologies (Wolters Kluwer Health)

ISSN (Electronic): 1536-0229

ISSN (Print): 0363-9762

Publication date (Electronic): Sep 2019

Volume: 44

Issue: 9

Affiliations

[1 ] From the Department of Nuclear Medicine, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong.

[2 ] Key Laboratory of Radiopharmaceuticals, Beijing Normal University, Beijing.

[3 ] Department of Neurology, National Key Clinical Department and Key Discipline of Neurology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong.

[4 ] Department of Radiology, University of Pennsylvania School of Medicine, Philadelphia, PA.

[5 ] Department of Nuclear Medicine, Xuanwu Hospital Capital Medical University, Beijing.

[6 ] Department of Neurology & National Clinical Research Center for Aging and Medicine, Huashan Hospital of Fudan University, Shanghai, China.

Article

DOI: 10.1097/RLU.0000000000002664

PubMed ID: 31205154

SO-VID: 2ca7ed8b-8737-4d64-a99c-1f4d9935e218

History

Data availability:

Comments

Comment on this article

scite_

Cited by 5

See all cited by